What Virginia Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Legal Risk

If you or a loved one has been taking Ozempic and is experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Medical literature has long recognized the importance of thorough drug safety monitoring, and recent attention has focused on the association between GLP-1 agonists like Ozempic and delayed gastric emptying. This page explains the FDA label context, exposure history, and what Virginia patients should watch for.

Medical Evidence: Ozempic and Gastroparesis Risk

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology includes slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This effect, while therapeutic for glycemic control, can also contribute to gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported with Ozempic at frequencies less than 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that gastrointestinal symptoms are common and can be severe enough to lead to discontinuation. The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action on GLP-1 receptors, which slows gastric motility. While this effect is intended to improve glycemic control, it can become pathological in susceptible individuals, leading to clinically significant delayed gastric emptying. The reported adverse reactions, including dyspepsia and gastroesophageal reflux disease, are consistent with impaired gastric motility. However, the prescribing information does not explicitly list gastroparesis as a warning or adverse reaction. The label includes a warning for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address the risk of gastroparesis.

Legal Risk Anchors for Virginia Patients

For patients in Virginia who have developed gastroparesis after using Ozempic, several risk factors are relevant. First, the adequacy of warnings is a central issue. The label does not mention gastroparesis as a potential adverse effect, despite the known pharmacological effect of delayed gastric emptying and the high frequency of gastrointestinal adverse reactions. This omission may affect whether patients were adequately informed of the risk before starting treatment. Second, the timeline between exposure and documented harm is critical. Gastrointestinal adverse reactions, including those that could indicate gastroparesis, often occur during dose escalation. Patients who experience persistent nausea, vomiting, or abdominal pain after starting Ozempic should seek medical evaluation. Documenting the onset of symptoms relative to drug initiation is important for establishing a temporal relationship. Third, attorney-related considerations for affected patients include the statute of limitations for product liability claims in Virginia. Virginia law generally allows two years from the date of injury to file a lawsuit. However, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the injury was caused by Ozempic. Patients should consult with a qualified attorney promptly to preserve their legal rights. In summary, the evidence shows that Ozempic is associated with a high rate of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's label does not explicitly warn about gastroparesis, which may be relevant for patients considering legal action. Virginia patients should be aware of the statute of limitations and seek legal advice if they have developed gastroparesis after using Ozempic.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in Virginia?

In Virginia, the statute of limitations for product liability claims is generally two years from the date of injury. However, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the injury was caused by Ozempic. It is crucial to consult with an attorney promptly to determine the applicable deadline.

Does Ozempic's label warn about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as a warning or adverse reaction. While gastrointestinal symptoms such as nausea, vomiting, and dyspepsia are reported, the label does not specifically address the risk of gastroparesis. This omission may be relevant for patients considering legal action.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.